Square Pharmaceuticals PLC. announcements
313 Dhaka Stock Exchange announcements for Square Pharmaceuticals PLC. (SQURPHARMA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2023 (26).
- Credit Rating Information and Services Limited (CRISL) has assigned rating of the Company as \"AAA\" in the long term an
Credit Rating Information and Services Limited (CRISL) has assigned rating of the Company as \"AAA\" in the long term and \"ST-1\" for short term along with Stable outlook in consideration of its audited financials up to June 30, 2023 also unaudited financials up to September 30, 2023 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Mr. Samuel S Chowdhury, one of the Directors of the Company, has expressed his intention to buy 1,000,000 shares of the
Mr. Samuel S Chowdhury, one of the Directors of the Company, has expressed his intention to buy 1,000,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange Limited within next 30 working days.
- Mr. Tapan Chowdhury, one of the Directors of the Company, has expressed his intention to buy 1,000,000 shares of the com
Mr. Tapan Chowdhury, one of the Directors of the Company, has expressed his intention to buy 1,000,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange Limited within next 30 working days.
- Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 1,000,000 shares of the compan
Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 1,000,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange Limited within next 30 working days.
- The company has informed that the Board of Directors in its meeting held on November 20, 2023 has approved an Equity par
The company has informed that the Board of Directors in its meeting held on November 20, 2023 has approved an Equity participation of USD 1.00 million by the Company in \"Samson Pharma Inc., Philippines\", a Company to be engaged in the marketing and distribution of pharmaceutical products, incorporated in the Philippines, out of its initial investment of USD 2.5 million. (cont.)
- Regarding Equity Participation and Contract Manufacturing Agreement
(Continuation news of SQURPHARMA): The Board of Directors also approved the Debt-Equity ratio @ 60:40 and expected time to start the business of Samson Pharma Inc. by April 2024. The Board of Directors further approved an agreement with M/S General Pharmaceuticals Ltd., Dhaka, Bangladesh, for contract manufacturing of products on behalf of the Company to meet the increased demand for an existing product. (end)
The first part of this announcement is missing from the archive. - The auditor of the company has given the \"Emphasis of Matters and Other Matter\" paragraph in the Auditor\'s Report of
The auditor of the company has given the \"Emphasis of Matters and Other Matter\" paragraph in the Auditor\'s Report of the company for the year ended June 30, 2023. To view the details, please visit: https://www.dsebd.org/assets/pdf/1.SQURPHARMA.pdf
- Resumption after Record date
Trading of the shares of the company will resume on 19.11.2023.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 6.77 for July-September 2023 as against Tk. 6.20 for July-September 2022; Consolidated NOCFPS was Tk. 9.54 for July-September 2023 as against Tk. 5.87 for July-September 2022. Consolidated NAV per share was Tk. 136.79 as on September 30, 2023 and Tk. 129.95 as on June 30, 2023.
- Suspension for Record date
Trading of the shares of the company will remain suspended on record date i.e., 16.11.2023.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 14.11.2023 to 15.11.2023 and trading of the shares will remain suspended on record date i.e., 16.11.2023.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
- The Board of Directors has recommended 105\% Cash Dividend for the year ended June 30, 2023. The Board has also approved
The Board of Directors has recommended 105\% Cash Dividend for the year ended June 30, 2023. The Board has also approved Tk. 400.00 crore for BMRE, Capital Machineries and Lands for future expansion. Date of AGM: 14.12.2023, Time: 10:00 AM, Venue: Digital Platform. Record Date: 16.11.2023. (cont.)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (23.10.2023) following its corporate declaration. However, the floor price shall be applicable accordingly.
- Dividend Declaration and BMRE, Capital Machineries & Land purchase
(Continuation news of SQURPHARMA): The Company has also reported Consolidated EPS of Tk. 21.41, Consolidated NAV per share of Tk. 129.95 and Consolidated NOCFPS of Tk. 9.64 for the year ended June 30, 2023 as against Tk. 20.48, Tk. 118.68 and Tk. 14.52 respectively for the year ended June 30, 2022. (end)
The first part of this announcement is missing from the archive. - Change of Board Meeting Time under LR 19(1)
The Company has further informed that, the Board meeting under LR 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, will be held on October 22, 2023 at 5:00 PM instead of 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 22, 2023 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- Regarding Contract Manufacturing Agreement with M/s Euro Pharma Ltd.
The company has informed that the Board of Directors in its meeting held on August 07, 2023 has approved an agreement with M/s Euro Pharma Ltd. for contract manufacturing of some products on behalf of the Company to meet increased demand of existing products and to introduce new products.
- Regarding Contract Manufacturing Agreement with M/s Aristopharma Ltd
The company has informed that the Board of Directors in its meeting held on July 12, 2023 has approved an agreement with M/s Aristopharma Ltd. for contract manufacturing of some products on behalf of the company to meet increased demand of existing products and to introduce new products.
- Name Change of the Company
Dhaka Stock Exchange Limited (DSE) has approved the proposed name change of the Company. Accordingly, the name of the Company will be 'Square Pharmaceuticals PLC.' instead of 'Square Pharmaceuticals Limited' with effect from June 22, 2023. Other things (except name) will remain unchanged.
- (Continuation news of SQURPHARMA): The Company has also informed that NOCFPS has been decreased due to amidst the ongoin
(Continuation news of SQURPHARMA): The Company has also informed that NOCFPS has been decreased due to amidst the ongoing complexity in the procurement of raw materials and protracted lead time, the Group has paid its regular suppliers in advance to ensure supply chain does not face any disruption. (end)
The first part of this announcement is missing from the archive. - Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 4.83 for January-March 2023 as against Tk. 5.15 for January-March 2022; Consolidated EPS was Tk. 16.82 for July 2022-March 2023 as against Tk. 16.03 for July 2021-March 2022. Consolidated NOCFPS was Tk. 10.95 for July 2022-March 2023 as against Tk. 13.87 for July 2021-March 2022. Consolidated NAV per share was Tk. 123.33 as on March 31, 2023 and Tk. 116.70 as on June 30, 2022. (cont.)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 30, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 5.78 for October-December 2022 as against Tk. 5.24 for October-December 2021; Consolidated EPS was Tk. 11.99 for July-December 2022 as against Tk. 10.88 for July-December 2021. Consolidated NOCFPS was Tk. 8.32 for July-December 2022 as against Tk. 10.89 for July-December 2021. Consolidated NAV per share was Tk. 118.53 as on December 31, 2022 and Tk. 116.70 as on June 30, 2022.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.